Arrhythmias and Hypertrophic Cardiomyopathy: Unravelling the Connection

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Hypertrophic cardiomyopathy (HCM) is a genetic heart disease affecting 1:200-1:500 individuals.
• Characterized by left ventricular hypertrophy, HCM involves sarcomeric gene mutations and autosomal dominant inheritance.
• HCM increases risks of heart failure, thromboembolism, and sudden cardiac death due to arrhythmias.

Purpose of the Study:

• To discuss the pathophysiology of arrhythmias in hypertrophic cardiomyopathy.
• To review clinical recommendations for managing atrial and ventricular arrhythmias in HCM patients.
• To highlight risk stratification for sudden cardiac death in HCM.

Main Methods:

• Literature review of HCM pathophysiology and arrhythmia mechanisms.
• Analysis of clinical guidelines for managing arrhythmias in HCM.
• Discussion of diagnostic and therapeutic strategies for HCM-related arrhythmias.

Main Results:

• HCM pathophysiology involves myocardial structural changes and triggers like exertion, leading to reentry and arrhythmias.
• Atrial fibrillation (AF) is common in HCM, necessitating anticoagulation and antiarrhythmic drugs.
• Ventricular arrhythmias, including sudden cardiac death, require risk assessment and interventions like ICDs.

Conclusions:

• Comprehensive analysis of clinical, anatomical, hemodynamic, functional, and genetic factors is crucial for risk stratification.
• Management strategies include long-term anticoagulation, antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillators (ICDs).
• Understanding arrhythmia mechanisms in HCM guides personalized treatment approaches to reduce mortality.